Dr. Freeman is a member of the Division of Molecular & Genomic Pathology and manages the Translational Pathology Imaging Laboratory. Dr. Freeman is the Medical Director of Biobank for NSABP/NRG Oncology Pittsburgh, an NCI-sponsored clinical trials cooperative that conducts national and international trials in breast and colorectal cancer.
Clinical Expertise
- Molecular and Genomic Pathology
- Tissue Banking
Education & Training
MD – Vanderbilt University School of Medicine - 2016
PhD – Vanderbilt University School of Medicine
Residency – University of Pittsburgh Medical Center – PIRRT Track – 2016 –2021
Fellowship – Molecular & Genomic Pathology - University of Pittsburgh Medical Center 2021-2022
Research Interests
- Molecular drivers of dedifferentiation in tumors
- Correlative science studies for clinical trials
Representative Publications
- Freeman T, Taneja C, Ohori NP, Wald A, Skaugen J, Yip L, Kim S, Ferris RL, Nikiforova MN, Roy S and Y Nikiforov. Identifying Metastatic Renal Cell Carcinoma in Thyroid Fine Needle Aspirates by Molecular Testing. Endocrine-Related Cancer. 2022. 29 (12): 657-664.
- McAuley J, Bailey K, Ekambaram P, Klei L, Kang H, Hu D, Freeman T, Concel, V, Hubel N, Lee J, Klei H, Cheng J, Sekar P, Bridwell R, Covic L, Lucas P and L McAllister-Lucas. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types. Oncogene. 2019.
- Means A, Freeman T, Zhu J, Woodbury L, Smith P, Wu C, Meyer A, Weaver C, Padmanabhan C., An H, Wessinger B, Chaturvedi R., Brown T, Deane N, Coffey R, Wilson K, Smith J, Sawyers C, Goldenring J, Novitskiy S, Washington M, Shi C and D Beauchamp. SMAD4 signaling within colon epithelium suppresses inflammation and inflammation-associated cancer. Cellular and Molecular Gastroenterology and Hepatology. 2018.
- McAuley J, Freeman T, Ekambaram P, Lucas P and L McAllister-Lucas. CARMA3 is a critical mediator of G protein-coupled receptor and receptor tyrosine kinase-driven solid tumor pathogenesis. Frontiers Immunology. 2018. 9:1887.
- Freeman T*, Smith J*, Chen X, Washington K, Roland J, Means A, Eschrich S, Yeatman T, Deane N, and R D Beauchamp. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of -catenin. Gastroenterology. 2012. 142(3): 562-571